肝动脉化疗栓塞术后胸腺法新联合索拉菲尼治疗中晚期肝癌的疗效分析

The therapeutic effect of thymalfasin combined with sorafenid in the treatment of advanced hepatocellular carcinoma after transcatheter arterial chemoembolization

目的:探讨中晚期肝细胞型肝癌患者肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)后索拉菲尼联合胸腺法新的疗效分析。方法:回顾性研究第四军医大学附属唐都医院54例中晚期原发性肝癌患者,所有患者均为乙型肝炎表面抗原阳性,并均接受了TACE手术治疗。在手术治疗后三天,开始口服索拉菲尼,以及皮下注射胸腺法新,观察患者的肝功能,计算治疗的有效率以及患者的生存时间。结果:观察组患者的总体有效率82.8%,显著高于对照组的56%,差异有统计学意义(P=0.032);观察组平均生存时间为13.8个月,对照组为10.2个月,可认为观察组生存时间长于对照组(P=0.021);治疗前两组AST、ALT以及白蛋白无明显差异(P>0.05);治疗3个月后与治疗前相比,两组的AST和ALT均得到改善(P<0.05),并且观察组白蛋白提高(P<0.001)。结论:胸腺法新、索拉菲尼联合TACE的治疗方法可以有效的改善肝炎病毒所致的原发性肝癌的预后,提高患者的生存期,值得临床推广。

Objective： To investigate the curative effect of sorafenid combined with thymalfasin in patients with advanced hepatocellular carcinoma after transcatheter arterial chemoembolization（ TACE）. Methods： The retrospective study of Tangdu Hospital affiliated to the Fourth Military Medical University included 54 cases of primary advanced liver cancer patients,all patients were hepatitis B surface antigen（ HBs Ag） positive,and underwent TACE. In three days after surgical treatment,all patients began to use sorafenib and thymalfasin. We observed the liver function,calculated the treatment efficiency and the survival time of the patients. Results： The efficiency of experimental group was82. 8%,which was significantly higher than 56% in the control group,and the difference was statistically significant（ P = 0. 032）. The average survival time for the experimental group was 13. 8 months,by contrast,the control group was 10. 2 months,and the survival time of experimental group was longer than the control group（ P = 0. 021）. There was no significant difference between the two groups on AST,ALT and albumin before treatment（ P〉 0. 05）. 3 months After treatment,the two groups of AST and ALT were improved（ P〈 0. 05）,and the albumin of experimental group increased（ P〈 0. 001）. Conclusion： The new method of sorafenid combined with thymalfasin after TACE treatment can effectively improve the prognosis of primary liver cancer caused by hepatitis virus,and can improve the survival of patients,so it is worthy of clinical promotion.